Corporate Member Genentech - NEW Approval

Corporate Member Genentech - NEW Approval

TECENTRIQ (Atezolizumab)
October, 2016

TECENTRIQ is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving TECENTRIQ.

 
 
Become a NOS Member Today!
 

Platinum Corporate Members

Gold Corporate Members